

# Index

## A

Accelerated aging, 253  
Acetylcholine, 209  
Actimetry, 278  
Adenosine, 160  
Adenosine-5'-triphosphate (ATP), 74, 80, 85  
Adipokines, 207–211  
Adiponectin, 210  
Adipose tissue, 203, 204, 207–211  
Adrenal cortex, 190, 191  
Adrenocorticotrophic hormone, 190–192  
Afterhours, 372  
Ageing, 211, 212  
AhrR. *See* Aryl hydrocarbon receptor (AhrR)  
Alcohol, 229, 230  
Amino acids, 233  
AMP kinase, 53, 245  
Angiotensin II, 13, 113, 117  
Anterior pituitary, 190  
Anteroventral periventricular nucleus (AVPV), 199, 200  
Apoptosis, 292, 297, 302  
ARC. *See* Arcuate nucleus (ARC)  
Arcuate nucleus (ARC), 188, 189, 199, 207  
Arginine vasopressin (AVP) and GRP, 49  
    signaling, 89, 95  
    V1aR, 110–111  
Aryl hydrocarbon receptor (AhrR), 245, 249  
Astrocytes, 114–116  
ATP. *See* Adenosine-5'-triphosphate (ATP)  
ATP/purinergic receptors, 115–116  
Autonomic nervous system, 191, 192, 203, 204, 206–209  
AVP. *See* Arginine vasopressin (AVP)  
AVPV. *See* Anteroventral periventricular nucleus (AVPV)

## B

Basic helix-loop-helix transcription factors, 167  
Behavioral rhythms, 367, 369, 372  
Behavioural testing, 176  
Biological clock, 188, 198, 201, 203, 206, 207, 210, 212  
Biomarker, 262, 274, 277, 279–281  
*Bmall*. *See* Brain and muscle Arnt-like protein-1 (*Bmall*)  
Body temperature, 4, 11, 12, 14, 15, 17, 18, 273, 279  
Brain and muscle Arnt-like protein-1 (*Bmall*), 5–9, 11, 12, 14, 15, 360, 363–367, 369, 373  
Brainstem, 209  
Brattleboro rats, 194

## C

Caffeine, 115, 116, 160, 326  
Cancer, 30, 34–40, 261–281  
    chronotherapeutics, 261–281  
    risk, 266  
    survival, 267  
Cardiotrophin-like cytokine (CLC), 113, 188  
Casein kinases, 7  
CBT. *See* Core body temperature (CBT)  
CCEs. *See* Clock-controlled elements (CCEs)  
Cell-autonomous circadian physiology  
    adrenal aldosterone production, 57  
    cardiac and adrenal tissues, 57  
    genome-wide technologies—ChIPseq, 55  
    kidney-intrinsic circadian oscillators and retinal clock, 56  
    PAR-B-ZIP transcription factors, 56, 57  
    REV-ERB $\alpha/\beta$ , 55–56

- Cell-autonomous circadian physiology (*cont.*)  
 rhythmic transcriptional control, 55  
 skeletal muscle and adipocyte tissues, 57
- Cell cycle, 263–265, 275, 276, 281
- Cerebral spinal fluid, 188, 189
- c-Fos, 200
- ChIP. *See* Chromatin immunoprecipitation (ChIP)
- ChIP-chip, 381–383
- ChIP-seq, 381–383
- Chromatin immunoprecipitation (ChIP)  
 chip and seq, 381–383  
 circadian cycle, 381  
 cross-link, 381  
 description, 380–381  
 and PCR and qPCR, 381  
 transcription factors, 381
- Chromatin remodeling, 31, 35
- Chronobiotics, 281
- Chronoefficacy, 263, 266–272, 280
- ChronoFLO, 270–272
- Chronomodulated therapy, 291, 292
- Chronopharmacodynamics, 276–277
- Chronopharmacokinetics, 276–277
- Chronopharmacology, 70–72
- Chronotherapy, 37–38, 261–281
- Chronotolerance, 263, 264, 266–272, 277, 280
- Chronotype, 273  
 CBT and sleep duration, 321  
 children and genetic influence, 322  
 internal phase relationships, 320–321  
 MCTQ, 320, 321  
 MEQ, 320–322  
 MSF, 320  
 rodents, 322  
 typical adolescent behaviour and genetic predisposition, 322
- CiRC. *See* Circadian integrative response characteristic (CiRC)
- Circadian, 3–19  
 biomarkers, 274, 279, 280  
 clock/oscillator, 162, 167, 170  
 disruption, 262, 278, 280  
 misalignment, 228  
 process, 158, 160, 161, 169, 175  
 rhythms, 262, 273, 276–279  
 synchrony, 88, 90  
 timing system, 262, 263, 273, 274, 278–281
- Circadian integrative response characteristic (CiRC), 319
- Circadian physiology  
 cell-autonomous, 55–57  
 direct endocrine control, 57–58  
 indirect control, 58  
 noncanonical clocks, 59
- Circadian signaling, drugs and effects  
 abundance/activity, receptors, 117  
 angiotensin II receptor antagonists, 117  
 caffeine, 116  
 neuropeptidergic receptors/signaling pathways, 116  
 neuropeptides, SCN, 116  
 pharmacology, 117  
 phase shifting, clock, 116
- Circadian transcriptomics  
 description, 382  
*Drosophila*, 382  
 microarray analysis, gene expression, 384, 385  
*Period* and *Cryptochrome* gene families, 382  
 RNA-seq, 384  
 tissue transcriptomes, 382, 384
- Cistrome, 8
- CLC. *See* Cardiostrophin-like cytokine (CLC)
- Clock, 3–19  
*Bmal1*, 134, 136, 139–141  
 controlled genes, 163, 168, 169  
 gene-knockout mice, 367  
 genes, 4, 5, 10–13, 15, 162–170, 174, 176, 262, 264–267, 275, 276, 360, 361, 363, 367, 369, 370, 372
- Clock-controlled elements (CCEs), 360–364, 367–371, 373
- Clock-mutant mouse, 162, 164, 167, 174
- Constant vs. entrained conditions, human circadian clock  
 basic free-running period ( $\tau$ ), 318  
 endogenous mechanism and free-running rhythms, 318  
 mice and *Drosophila*, 319  
*Neurospora crassa* and CiRC, 319  
 PRCs, 318–319
- Core body temperature (CBT), 321
- Corticosterone, 190–193, 195, 196, 198
- Corticotrophin-releasing hormone, 189–192
- Cortisol, 262, 273, 279–281
- Critical illness, 202, 203
- Cry. *See* Cryptochrome (Cry)
- Cry1, 245, 252

Cryptochrome (Cry), 6–9, 12, 15, 16  
 Cytochrome P450, 248  
 Cytokines, 56, 58, 107, 113, 188, 209, 211, 263

## D

Daylight savings time (DST), 323, 324, 327  
 D-box-binding protein (DBP), 248, 249  
 DBP. *See* D-box-binding protein (DBP)  
 DDEs. *See* Delay differential equations (DDEs)  
 Deiodinase, 201  
 Delay, 359–373  
 Delay differential equations (DDEs), 337–339, 347, 349–352  
 Denervation, 191, 203, 204, 209  
 Deoxyribonucleic acid (DNA)  
 “chip”, 381  
 damage, 291–297, 301, 303  
 repair, 291, 292, 294–296  
 Depression, 202  
 Detoxification, 263, 277  
 dGAL4, 370  
 dGAL4-VP16, 370  
 Dichotomy index, 278  
 Direct, 128–133, 139–142  
 Direct nervous stimuli  
 autonomous nervous system, 51  
 GABAergic input and clock gene expression, 51  
 parasympathetic nervous system and phase-shift cellular clocks, 51  
 sleep and arousal regulations, 51  
 SPVZ, 50–51  
 Diurnal, 189, 191, 192, 201–203  
 DNA. *See* Deoxyribonucleic acid (DNA)  
 DNA-intercalating agents, 269  
 Dopamine receptor, 231  
 Dorsomedial hypothalamus, 189–192, 198, 200, 205  
 Drugs, 234, 235  
 DST. *See* Daylight savings time (DST)

## E

EEG. *See* Electroencephalogram (EEG)  
 Efficacy, 262, 263, 266, 268, 270, 272, 273, 276–278, 280, 281  
 Efficacy of chronotherapeutic treatment, 344  
 Electroencephalogram (EEG)  
 delta power, 164–169  
 slow wave activity (SWA), 159, 160, 163, 166, 169, 173  
 theta activity/power, 160, 169

## Entrainment

characteristic, oscillators, 49–50  
 chronotype, 320–322  
 constant vs. entrained conditions, 318–319  
 direct nervous stimuli, 50–51  
 intrinsic period, 316–317  
 peptides and hormones, 51–52  
 SCN, 54–55  
 signals, SCN to peripheral oscillators, 50  
 single cells, 340–344  
 social jetlag, 325–326  
 social zeitgebers, 317–318  
 temperature and feeding, 53–54  
 zeitgeber, 322–325  
 ENU-mutant, 372  
 Environmental enrichment/novelty, 173  
 Epigenetics, 29–40  
 Excitatory amino acids (EAAs), 116  
 Exercise, 212  
 Experimental models, 275, 280

## F

Familial advanced sleep-phase syndrome (FASPS), 4, 371, 372  
 FASPS. *See* Familial advanced sleep-phase syndrome (FASPS)  
 F-box and leucine-rich repeat protein 3 (FBXL3), 7  
 FBXL3. *See* F-box and leucine-rich repeat protein 3 (FBXL3)  
 Fibroblast  
 cultured mammalian skin, 46, 48  
 RAT1, 52  
 FOLFOX2, 270, 272  
 Food anticipatory activity, 246  
 Forced desynchrony, 160  
 Free fatty acids, 208, 209  
 Free-running period  
 central quality/dogma, circadian system, 316  
 entrainment models, 318  
 intrinsic, 316  
 temperature compensation, 313

## G

GABA. *See* Gamma-aminobutyric acid (GABA)  
 Gamma-aminobutyric acid (GABA), 90, 112–113, 191, 192, 194, 195, 197, 198, 204–208  
 Gastric pH, 246, 247

Gastrin releasing peptide (GRP)  
 and AVP, 49  
 signaling, 90  
 Gender differences, 270, 274  
 Genetic complementation assay, 365  
 Genome-wide analysis  
 bacteria to mammals, 380  
 cells and tissues, 380  
 ChIP-chip and ChIP-seq, 381–383  
 ChIPing away at chromatin, 380–381  
 circadian transcriptomics, 382–384  
 clock-relevant transcription factors, 380  
 cyanobacterium, 380  
 DNA and RNA, 379  
 24-h timescale, 379  
 interferomics and manipulating, 384–386  
 transcription, 386  
 Genotoxic stress, 291–297, 302  
 GFAP. *See* Glial fibrillary acidic protein (GFAP)  
 Glia, circadian system  
 astrocytes communication, 114  
 ebony, 114  
 GFAP and SCN, 113–114  
 glia-to-neuron signaling, 116  
 in vivo and in vitro, 113  
 mammals, 114  
 neuron-to-glia signaling, 114–116  
 protein and mRNA levels, 114  
 Glial fibrillary acidic protein (GFAP), 113, 114  
 Glia-to-neuron signaling, 116  
 Gliotransmission, 114  
 Glucocorticoid receptor (GR), 52, 252  
 Glucose, 203–210, 212  
 Glutamate, 73, 188, 195–198, 204–206  
 Glutathione-S-transferase (GST), 248  
 Gonadotropin inhibitory hormone, 200  
 Gonadotropin-releasing hormone, 189–200  
 GPCR. *See* G-protein coupled receptor (GPCR)  
 G-protein coupled receptor (GPCR), 90, 252  
 GR. *See* Glucocorticoid receptor (GR)  
 GRP. *See* Gastrin releasing peptide (GRP)  
 GRP/BBR2, 109–110  
 GST. *See* Glutathione-S-transferase (GST)

## H

HAI. *See* Hepatic arterial infusion (HAI)  
 HAT. *See* Histone acetyltransferase (HAT)  
 HDAC. *See* Histone deacetylase (HDAC)  
 Heme, 235  
 Hepatic arterial infusion (HAI), 270, 272

Hepatic leukemia factor (HLF), 246, 248, 249  
 High-throughput screening, 297–303  
 Histone acetylation, 31–33, 35  
 Histone acetyltransferase (HAT), 7, 32, 245, 252  
 Histone deacetylase (HDAC), 32, 33, 35  
 Histone demethylase, 35  
 Histone methylation, 31, 32  
 HLF. *See* Hepatic leukemia factor (HLF)  
 Homeostatic  
 process, 158, 159, 170  
 Hopf bifurcation, 339, 349–350  
 Hormones  
 agomelatine, 234  
 ghrelin, 233  
 leptin, 233  
 melatonin, 228  
 HPA. *See* Hypothalamic-pituitary-axis (HPA)  
 Human circadian clock  
 biological clocks and circa-24-h rhythmicity, 313  
 chronobiology, 312  
 description, 312  
 entrainment (*see* Entrainment)  
 programme, 312  
 sleep per se and bedroom behaviour, 327  
 temperature compensation and single-cell organisms, 313  
 ‘unforced’ sleep timing and DST, 327  
 velocity and mechanism, 313  
 zeitgeber, 313–314  
 zeitnehmer, 314–315  
 Hypertension, 211, 212  
 Hypothalamic-pituitary-axis (HPA), 142  
 Hypothalamic-pituitary-gonadal, 198, 200  
 Hypothalamo-pituitary-thyroid, 201, 202

## I

Image forming (IF) responses, 170  
*In silico*, 281  
 Insulin, 188, 204, 206, 208–210  
 Intercellular coupling, 340, 341  
 Interferomics  
 canonical kinase pathways, 384, 386  
 clock gene, 384  
 description, 384  
 pre-eminent assay system, 384  
 RNAi, 384  
 siRNAs, 384  
 transcription–translation feedback loop, 386  
 Intersubject differences, 272

Intrinsic period, human circadian clock  
 damped clock and sleep, 316  
 internal day and steady-state  $\tau$ , 317  
 intrinsic free-running period, 317  
 self-created LD cycle and light exposure,  
 316  
 sleep–wake cycle, 316–317  
 zeitnehmer loops and oscillators, 316  
*In vitro*, 274, 281  
*In vivo*, 274, 281

## K

Kinases  
 casein kinases, 228, 234  
 ERK2, 234  
 GSK3beta, 234  
 Kisspeptin, 199, 200

## L

Leptin, 188, 209, 210  
 Light as zeitgeber, human circadian clock  
 chronotype and geographical locations,  
 322, 323  
 dependencies varying, season, 323, 325  
 MCTQ, 323  
 people spend outdoors, 323, 324  
 seasonal changes in phase, entrainment,  
 323, 324  
 Light/dark, 127, 129, 137, 138, 143  
 Light therapy, 234  
 Limit cycle oscillator, 339–342, 352, 353  
 Linear chain trick, 351  
 Lipid absorption, 247  
 Lipolysis, 208, 209  
 Lithium, 229, 231, 234  
 Little SAAS, 111–112

## M

Mammals, peripheral clocks. *See* Peripheral  
 clocks  
 MAO-A. *See* Monoamine oxidase A (MAO-A)  
 Mass spectrometry, 390, 392, 400, 402  
 Mathematical modeling, 274–278, 281  
 MCTQ. *See* Munich chronotype questionnaire  
 (MCTQ)  
 Medial preoptic area, 189, 198–200  
 Melanin-concentrating hormone, 205  
 Melatonin, 188, 192–198, 202, 204, 205,  
 210–212, 273, 279, 281  
 agonists, 172

receptors, 172  
 sleep promoting action/effect, 172  
 Mental health disorders, 174  
 MEQ. *See* Morningness–eveningness  
 questionnaire (MEQ)  
 Metabolic syndrome, 29–30, 39, 233  
 Metabolomics, 386, 400  
 Microdialysis, 191, 195, 196, 198, 199, 209  
 Mid-phase of sleep on free days (MSF), 320  
 Modeling chronotherapy, 344–345  
 Molecular models, 3–19, 275, 276  
 Monoamine oxidase A (MAO-A), 250  
 Mood disorders  
 bipolar disorder, 229, 231  
 depression, 228, 229, 231, 234  
 schizophrenia, 229  
 seasonal affective disorder (SAD), 228,  
 229, 231  
 Morningness–eveningness questionnaire  
 (MEQ), 320–322  
 MSF. *See* Mid-phase of sleep on free days  
 (MSF)  
 Munich chronotype questionnaire (MCTQ),  
 273, 320, 321  
 Mutagenesis, 166

## N

NAD<sup>+</sup>, 33, 34  
 NAMPT. *See* Nicotinamide  
 phosphoribosyltransferase (NAMPT)  
 Negative feedback, 336–340, 346–350, 361,  
 365, 367, 371, 372  
 Negative feedback loop, 360, 364–367,  
 369, 373  
 Neuroendocrine neurons, 188–190, 192  
 Neuromedin U, 191  
 Neuronal activity, 195, 209  
 Neuronal PAS domain protein 2 (NPAS2), 12  
 Neuron–neuron signaling in SCN  
 AVP/V1aR, 110–111  
 CLC, 113  
 cognate receptors, 107–108  
 GABA, 112–113  
 GRP/BBR2, 109–110  
 intercellular communication, 107  
 little SAAS, 111–112  
 VIP/VPAC2R, 108–109  
 Neurons, SCN  
 alarm clock/master circadian pacemaker,  
 105  
 central timer in vivo and in vitro, 105–106  
 circadian system, 106

- Neurons (*cont.*)
- competent circadian pacemakers, 106
  - dorsal shell and ventral core, 107
  - intracellular molecular events, 106
  - multi-oscillator system, 107
  - neuron signaling (*see* Neuron–neuron signaling in SCN)
  - population, heterogeneous, 107
- Neuron-to-glia signaling
- ATP/purinergic receptors, 115–116
  - cFOS expression, 114–115
  - in vivo*, circadian rhythms in ATP, 114
  - mouse motor cortex, 114
  - VIP/VPAC2R, 115
- Neuro psychiatric disorders, 174
- Neurotransmitters, 250
- dopamine, 230
  - glutamate, 233
- Nicotinamide phosphoribosyltransferase (NAMPT), 245
- Nocturnal, 190–192, 194, 195, 197, 198, 201–203
- Noise-driven oscillations, 340–342, 352
- Non-image forming (NIF) responses, 170, 171
- Non-transcriptional rhythms, 9–10
- NPAS2. *See* Neuronal PAS domain protein 2 (NPAS2)
- NPAS2/*Bmal1*, 140
- Nuclear receptors, 233, 235
- O**
- Obesity, 208, 210, 211, 233, 235
- ODEs. *See* Ordinary differential equations (ODEs)
- Oestrogen receptors, 198–200
- Opponent process model, 161
- OPTILIV, 272
- Optimal phase of chronotherapeutic treatment, 345
- Optimization, 266, 274, 275, 277–278
- Ordinary differential equations (ODEs), 276
- Orexin, 205–207
- Overexpression, 364
- Overtime, 372
- Oxaliplatin, 268–273, 276
- Oxidative stress, 252
- P**
- Pancreas, 203, 206, 207
- Paralog compensation, 7
- Parasympathetic, 201, 203, 204, 206, 208, 209
- Paraventricular nucleus (PVN)
- circadian glucose production in liver, 51
  - hypothalamus, 188–198, 201, 202, 204, 206
- PAR-B-ZIP. *See* Proline and acidic amino acid-rich basic leucine zipper (PAR-B-ZIP)
- Partial differential equations (PDEs), 276
- PCR. *See* Polymerase chain reaction (PCR)
- PDEs. *See* Partial differential equations (PDEs)
- Peptides and hormones
- control, diurnal behavior, 51
  - daily fashion and glucocorticoid receptor (GR), 52
  - diffusible factors, SCN, 52
  - myriad, signals controls circadian phase, 52
  - phase-shifting peripheral circadian clocks and multiple signaling agents, 52
  - pituitary–adrenocortical axis and signaling pathways, 52
- Per*, 5–9, 13, 14, 16
- Per1*, 198, 361–363, 367, 372
- Perifornical area, 205, 207
- Peripheral clocks
- Bmal1* gene, 47
  - circadian physiology (*see* Circadian physiology)
  - CLOCK and BMAL1 proteins, 47
  - direct and indirect signals, 59
  - DNA “reporters” and fruit flies, 46
  - entrainment, 49–55
  - genes and proteins, 47–48
  - “master clock” pacemaker neurons, 46
  - mechanism, circadian clocks, 46
  - network synchrony, 48–49
  - nuclear-receptor-mediated physiology, 60
  - nuclear receptor ROR and REV-ERB proteins, 47
  - Rev-Erba* gene, 47
  - SCN (*see* Suprachiasmatic nucleus (SCN))
- Personalized chronotherapy schedules, 281
- Perturbation, 363–364
- p-Glycoprotein, 246
- PGRC. *See* Photosensitive retinal ganglion cells (PGRC)
- Phase, 363, 367, 370, 371
- Phase II metabolism, 248
- Phase response curves (PRCs), 318–319
- Phase vector model, 365, 367
- Photoentrainment, 170
- Photoreceptors
- cones, 170, 171
  - melanopsin, 170, 171
  - rods, 170, 171

- Photosensitive retinal ganglion cells (PGRC), 170  
 Pineal gland, 192–198, 201, 203  
 PK2. *See* Prokineticin 2 (PK2)  
 Plasma proteins, 247  
 Poly-ADP polymerase, 245  
 Polymerase chain reaction (PCR), 381  
 Post-translational circadian oscillator, 373  
 Post-translational control, 372, 373  
 Post-translational regulation, 360, 371–373  
 PPAR- $\alpha$ . *See* Proliferator-activated receptor alpha (PPAR- $\alpha$ )  
 PPAR- $\gamma$ , 251  
 PRCs. *See* Phase response curves (PRCs)  
 Pre-autonomic neurons, 188, 189, 194, 197, 198, 201, 203–208  
 Prognostic, 273, 278, 280  
 Programmable pumps, 266  
 Prokineticin 2 (PK2), 52, 188  
 Proliferator-activated receptor alpha (PPAR- $\alpha$ ), 251  
 Proline and acidic amino acid-rich basic leucine zipper (PAR-B-ZIP), 56–57, 248, 251  
 Propranolol, 247  
 Proteomics  
   cells and tissues, 380  
   datasets, 386  
   expression, 390–396, 401, 402  
   interaction, 390–399, 401  
   and metabolomics, 386  
   quantitative, 390, 391, 393, 395–397, 400–402  
 Purinergic receptor, 115–116  
 PVN. *See* Paraventricular nucleus (PVN)
- Q**
- qPCR. *See* Quantitatively using real-time PCR (qPCR)  
 Quantitatively using real-time PCR (qPCR), 381
- R**
- Ramelteon, 172  
 Repressilator, 366, 369  
 Resistin, 211  
 Rest–activity, 262, 273, 278–280  
 Reticular thalamic nucleus, 172  
 Retina, 4, 11, 13  
*Rev-Erb* genes, 9  
 Reward system  
   amygdala (AMY), 229, 230  
   nucleus accumbens (NAc), 229, 230  
   prefrontal cortex (PFC), 229, 230  
   striatum, 231  
   ventral tegmental area (VTA), 229, 230, 233  
 RF-amide-related peptide, 200  
 Rhythms, 128–135, 137–145  
 RNAi. *See* RNA interference (RNAi)  
 RNA interference (RNAi), 384  
 RNA-seq, 384
- S**
- SCN. *See* Suprachiasmatic nucleus (SCN)  
 SD. *See* Sleep deprivation (SD)  
 Selective serotonin reuptake inhibitors (SSRIs), 251  
 Selenium, 301, 302  
 Senescence, 292, 296–297  
 Serotonin, 250, 251  
 Single cell modeling, 340, 341, 352  
 Single nucleotide polymorphisms (SNPs), 229, 231  
 siRNAs. *See* Small interfering RNAs (siRNAs)  
 SIRT1, 32–34, 245  
 Skin surface temperature, 279  
 Sleep, 187, 193, 196, 201–206, 211  
   active neurons, 159  
   deprivation, 158–161, 163, 164, 166–169, 173  
   homeostasis, 158–163, 166–170, 172, 174–176  
   regulation, 158–176  
   spindles, 167  
   wake, 128, 131, 133, 137  
 Sleep deprivation (SD), 234  
 Small interfering RNAs (siRNAs), 384  
 SNPs. *See* Single nucleotide polymorphisms (SNPs)  
 Social cues/interactions/conflict, 173–174  
 Social jetlag  
   alarm clocks and chronic phenomenon, 325  
   description, 325  
   discrepancy internal and external time, 325  
   internal and external timing, 325–326  
   MSW and MSF, 325, 326  
   shorter habitual sleep and MCTQ database, 325  
   symptoms and travel-induced, 325

- Social zeitgebers  
 Andechs bunker experiments, 318  
 blindness types and circadian rhythms, 317  
 non-photic signals, 317–318
- Spinal cord, 193, 205, 207
- Splitting, 191, 200
- SPVZ. *See* Subparaventricular zone (SPVZ)
- SSRIs. *See* Selective serotonin reuptake inhibitors (SSRIs)
- Subparaventricular PVN (subPVN), 189, 191, 192, 198
- Subparaventricular zone (SPVZ), 50
- subPVN. *See* Subparaventricular PVN (subPVN)
- Superior cervical ganglion, 193, 195
- Suprachiasmatic nucleus (SCN), 5, 8, 10–18, 72–79, 83, 87–96, 188–201, 203–212  
 astrocyte release, 116  
 cells vs. intact slices, 49  
 clock protein and fibroblasts, 47  
 controlled behavior, 46–47  
 diffusible factors, 52  
 direct cascades leading, 53  
 driven timing signals, 49–50  
 electrical activity, 161, 169  
 and GFAP, 113–114  
 hypothalamus, 45  
 indirect and entrainment signals, 54  
 intermittent oscillations, 48  
 lesions, 159–162, 170  
 light-dependent phase shifting, 54–55  
 nervous signals and hormone, 54  
 neuron populations in vitro and lesioned animals, 49  
 neurons (*see* Neurons, SCN)  
 peripheral and “master” clocks, 46  
 to peripheral oscillators, 50  
 rhythmic gene expression and electrical activity, 48  
 temperature resistance and network properties render, 54  
 timing signals to multiple tissues and PVN controls, 51  
 VIP/VPAC2R, 115
- Survival, 262, 266, 267, 270, 272–274, 278, 280
- Sympathetic, 193, 197, 201, 203–209
- Synchronization of circadian oscillators, 340–344
- Synthetic approach, 369
- T**
- Tau* mutation, 7, 12, 371
- TEF, 248
- Temperature and feeding  
 AMPK and circadian clock function, 53  
 cells and living mammals, 53  
 CLOCK and BMAL1, 53  
 dependent hormones and cryptochrome clock proteins, 53  
 ghrelin, 53–54  
 glucocorticoids and homeotherms, 53  
 patterns and NAD<sup>+</sup>, 53
- Temporal expression, 361
- Tetrodotoxin, 195
- TGF $\alpha$ . *See* Transforming growth factor alpha (TGF $\alpha$ )
- Therapeutic index, 344
- Thyroid gland, 201, 202
- Thyroid hormones, 201–203
- Thyrotrophin-releasing hormone (TRH), 189, 201–203
- Time delay, 360, 367
- Time-restricted feeding, 197
- Toxicity, 263, 264, 269, 270, 272, 273, 275–278
- Tracing, 189–191, 194, 200, 201, 203, 205, 209
- Transcriptional feedback loops, 162, 168–170, 336, 339
- Transcriptome analysis, 361
- Transcriptomics, 390, 392, 394, 396, 401
- Transforming growth factor alpha (TGF $\alpha$ ), 52
- Translational feedback loops, 162, 168–170
- Transneuronal virus tracing, 191, 201
- Transplantation, 189, 191
- TRH. *See* Thyrotrophin-releasing hormone (TRH)
- Triglycerides, 207, 208
- Two process model, 158
- Type 2 diabetes, 211
- V**
- Vasoactive intestinal polypeptide (VIP), 49, 169, 188, 189, 191, 194, 200  
 neuron-neuron signaling in SCN, 108–109  
 neuron-to-glia signaling, 115  
 signaling, 90, 91
- Vasopressin (VP), 188–191, 194, 198–200, 211
- Ventrolateral preoptic area (VLPO), 159–161, 171
- Ventromedial nucleus of the hypothalamus (VMH), 206–208



VIP. *See* Vasoactive intestinal polypeptide (VIP)

Visfatin, 211

VLPO. *See* Ventrolateral preoptic area (VLPO)

VMH. *See* Ventromedial nucleus of the hypothalamus (VMH)

VP. *See* Vasopressin (VP)

## W

Weakly damped oscillator, 340, 341, 343, 346, 352, 353

Whole-body modeling, 277

## Z

Zeitgeber

circadian clock and temperature, 314

environmental factor and evolutionary oldest clocks, 313

LD cycles, 313

light, 322–326

plants and animals, 326

single-cell organism *Lingulodinium*, 313–314

social, 317–318

## Zeitnehmer

cellular clocks and entrainment process, 315

clock's rhythm generation, 314

dual role, circadian clocks, 314

feedbacks and central pacemaker, 314

PRC concept and temperature forming, 315

SCN's entrainment mechanism, 314–315